Pharsight

Drugs that contain Eliglustat Tartrate

1. Cerdelga patents expiration

CERDELGA's oppositions filed in EPO
CERDELGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6916802 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(2 years ago)

US7196205 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Jun, 2026

(2 years from now)

US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7253185 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(2 years ago)

US7615573 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Apr, 2022

(2 years ago)

US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(6 years from now)

US10888544 GENZYME CORP Methods for treating Gaucher disease
Dec, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Aug 19, 2021
New Chemical Entity Exclusivity(NCE) Aug 19, 2019
Orphan Drug Exclusivity(ODE-73) Aug 19, 2021

NCE-1 date: 19 August, 2018

Market Authorisation Date: 19 August, 2014

Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent ...

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage

CERDELGA family patents

Family Patents